- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02981355
Randomized Evaluation of BST-CarGel Versus Microfracture Alone On Recovery From Distal Femoral Cartilage Lesions (RECORD)
Study Overview
Status
Intervention / Treatment
Detailed Description
The current standard of treatment for cartilage lesions on the femoral condyle is microfracture, which is conducted by penetrating the subchondral bone below the lesion. This procedure creates a natural healing response as a result of the bleeding and clotting caused by the microfracture, restoring the lesion. BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division), a liquid chitosan-containing polymer scaffolding, has been developed as an intra-articular injectable scaffold to aid in the stabilization of the blood clot created by microfracture. BST-CarGel does not interfere with the normal clotting process; however, it enables a prolonged healing time due to the increased stabilization of the clot within the lesion and the inhibition of clot retraction.
The RECORD trial is a multi-centre, randomized, controlled trial to assess the impact of the BST-CarGel scaffold and microfracture versus microfracture alone on short term clinical benefit as measured by loaded knee pain (single leg squat) on a visual analogue scale (3-6 months), mid-long term clinical benefit as measured by the same loaded knee pain (single leg squat) (9, 12, and 24 months) and Tegner Activity Score (TAS), International Knee Documentation Committee (IKDC), and Knee Injury and Osteoarthritis (KOOS) at 3, 6, 9, 12 and 24 months post-operatively. Approximately 158 participants with full-thickness grade III and IV cartilage lesions will be randomised in a 1:1 ratio to receive one of the two treatments during an arthroscopic procedure and will be followed for up to 24 months to collect outcomes.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia, 5000
- Calvary Wakefield Hospital
-
Murdoch, Australia, 6150
- Murdoch Orthopaedic Clinic
-
-
-
-
-
Banff, Canada, T1L1B3
- Banff Sport Medicine
-
London, Canada, N6A3K7
- Fowler Kennedy Sport Medicine Clinic
-
Montreal, Canada, H1T4B3
- Hôpital Maisonneuve-Rosemont
-
-
-
-
-
Lyon, France, 69004
- Hôpital de la Croix-Rousse
-
Nancy, France, 54000
- CHRU Nancy - Hospital Central
-
-
-
-
-
Regensburg, Germany, 93042
- University Medical Centre Regensburg
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08023
- Hospital Quironsalud Barcelona
-
Barcelona, Spain, 08003
- Hospital Universitari del Mar
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
-
Zurich, Switzerland, 8032
- SportClinic Zurich / Hirslanden Clinic
-
-
-
-
-
Birmingham, United Kingdom, B312AP
- The Royal Orthopaedic Hospital
-
Southampton, United Kingdom, S0166YD
- University Hospital Southampton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- requires cartilage repair treatment due to distal femoral cartilage lesion
- is 18-55 years of age at the time of surgery
- has single, focal cartilage lesion on one of the femoral condyles
- has symptomatic cartilage lesion that has failed conservative management
- has a single lesion classified as focal, full-thickness grade 3 or 4 according to the ICRS (3A, 3B, 3C, 3D and 4A)
- an area of lesion between 1.5-3 cm2 after debridement
- has a stable knee (<5-mm side-to-side difference on Lachman and varus and valgus stress testing and grade 0 or 1 on the pivot-shift test) and an intact meniscal rim
- is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires and recommended physiotherapy regimen
- has agreed to discontinue the use of all knee pain medication 3 days before the pre-treatment visit and the post-treatment follow-up visits at 3, 6, 9, 12, and 24 months
- has consented to participating in the study by signing the IRB/EC approved informed consent form
- no deep osteochondral defect ( < 5 mm bone loss)
Exclusion Criteria:
- has multiple lesions or kissing (opposing) lesion(s) greater than GII
- has clinically relevant compartment malalignment (>5°)
- has bone cyst(s) associated with, or adjacent to, the index lesion
- has Osteochondritis Dissecans with bone or bone-cartilage fragment in place
- has had ligament treatments in the index knee within the previous 24 months
- has had surgical cartilage treatments in the index knee within previous 12 months
- has had intra-articular injections in the index knee within the previous 2 months
- has diagnosis of an immunosuppressive disorder
- has a BMI > 30 kg/m2
- has concomitant healing bone fractures
- has a single lesion classified as focal, full-thickness grade 4B as defined by ICRS
- has noteworthy pain in the ipsilateral hip or ankle or contralateral hip, knee, or ankle
- has inflammatory arthropathy
- has blood clotting disorders, was receiving anticoagulant therapy, or has recurring deep vein thrombosis
- has a serious heart condition or liver and/or renal abnormalities diagnosed within the previous 24 months
- has chronic infection of the lower joint extremities
- has a history of alcohol or drug abuse within the previous 12 months
- is facing current or impending incarceration
- has a known allergy to shellfish
- is pregnant or plans to become pregnant during the course of the study
- in the opinion of the PI, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, drug or alcohol abuse
- chronic knee pain
- has a documented medical history of vitamin-D deficiency that is not being managed with supplementation
- is entered in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days
- requires an open procedure
- is known to be at risk for lost to follow-up, or failure to return for scheduled visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Microfracture treatment
Microfracture surgery of the femoral condyle
|
Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
|
EXPERIMENTAL: BST-CarGel plus microfracture treatment
BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
|
Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in loaded knee pain (single leg squat) visual analogue scale (VAS)
Time Frame: Baseline to 24 months post-surgery
|
Used to demonstrate patient clinical improvement.
The VAS is one of the most commonly used measures of pain intensity, where the patient rates their pain on a scale from 0 to 10 (0=no pain; 10=maximum pain possible).
|
Baseline to 24 months post-surgery
|
Change in knee function measured by the TAS questionnaire
Time Frame: Baseline to 24 months post-surgery
|
The TAS is a validated patient-administered questionnaire for use in multiple knee injuries and consists of a numerical scale ranging from 0 to 10 to indicate the ability to perform specific activities.
|
Baseline to 24 months post-surgery
|
Change in knee function measured by the IKDC questionnaire
Time Frame: Baseline to 24 months post-surgery
|
The IKDC measures the progress in symptoms, function, and sports activities caused by knee impairment after a treatment has been performed.
It can be used with reliability and validity in patients with a range of knee conditions.
|
Baseline to 24 months post-surgery
|
Change in knee function measured by the KOOS questionnaire
Time Frame: Baseline to 24 months post-surgery
|
The KOOS is a measure of a patient's perceived knee pain and function, as well as associated problems with their knee status.
It contains 42 items that are all recorded on a five-point Likert Scale by the patient.
|
Baseline to 24 months post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Repair tissue quantity and quality
Time Frame: Up to 24 months post-surgery
|
Measured by MOCART Score and percentage lesion fill.
The MOCART Score will be completed by two independent, blinded, well-trained radiologist readers.
|
Up to 24 months post-surgery
|
Adverse events related to treatment
Time Frame: Up to 24 months post-surgery
|
Up to 24 months post-surgery
|
|
Economic evaluation
Time Frame: surgical visit, 2 weeks, 6 weeks, 3 months, 6 months, 9 months,12 months and 24 months post-surgery
|
Measured by study-specific Resource Utilization Questionnaires which will be used to determine the costs associated with the use of the BST-CarGel scaffold treatment.
|
surgical visit, 2 weeks, 6 weeks, 3 months, 6 months, 9 months,12 months and 24 months post-surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jean-Pierre Desmarais, Piramal Healthcare Canada Ltd
Publications and helpful links
General Publications
- Shive MS, Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Methot S, Vehik K, Restrepo A. BST-CarGel(R) Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial. Cartilage. 2015 Apr;6(2):62-72. doi: 10.1177/1947603514562064.
- Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Restrepo A, Shive MS. Novel scaffold-based BST-CarGel treatment results in superior cartilage repair compared with microfracture in a randomized controlled trial. J Bone Joint Surg Am. 2013 Sep 18;95(18):1640-50. doi: 10.2106/JBJS.L.01345.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BST-CarGel Pr001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Lesion of Articular Cartilage of Knee
-
Episurf Medical Inc.MCRARecruitingDegenerative Lesion of Articular Cartilage of KneeUnited States, Canada, Germany, United Kingdom
-
Ettore Sansavini Health Science FoundationCompletedDegenerative Lesion of Articular Cartilage of KneeItaly
-
Barmherzige Brüder EisenstadtUnknownDegenerative Lesion of Articular Cartilage of Knee | Osteochondral Lesion of Talus
-
University Hospital, Basel, SwitzerlandDeutsche Arthrose-HilfeCompletedDegenerative Lesion of Articular Cartilage of Knee | Cartilage LesionSwitzerland
-
Middle East Technical UniversityCompletedOsteoarthritis | Degenerative Lesion of Articular Cartilage of Knee | Articular Cartilage Disorder of KneeTurkey
-
University of Colorado, DenverStanford University; University of KentuckyRecruitingDegenerative Lesion of Articular Cartilage of KneeUnited States
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CellCoTec B.V.CompletedArticular Cartilage Lesion of the KneeBelgium, Poland, United Kingdom
-
Biosolution Co., Ltd.Kyung Hee University HospitalCompletedArticular Cartilage Lesion of Knee
-
Zimmer Orthobiologics, Inc.UnknownDegenerative Lesion of Articular Cartilage of Knee | Osteochondritis DissecansUnited States
Clinical Trials on Microfracture treatment
-
Medipost Co Ltd.CompletedOsteoarthritis | Cartilage InjuryKorea, Republic of
-
Medipost Co Ltd.Dong-A Pharmaceutical Co., Ltd.CompletedDefect of Articular Cartilage | Degenerative OsteoarthritisKorea, Republic of
-
Zealand University HospitalSuspended
-
The Catholic University of KoreaUnknown
-
Bergen Orthopedic Study GroupCompleted
-
Histogenics CorporationTerminatedArticular Cartilage Defects in the Knee JointUnited States, Canada
-
Sewon Cellontech Co., Ltd.UnknownOsteoarthritis | Defect of Articular Cartilage | Traumatic ArthritisKorea, Republic of
-
L&C BioActive, not recruitingOsteoarthritis, KneeKorea, Republic of
-
Nova Scotia Health AuthorityWithdrawnDisorder of Hip Region
-
HistogenUnited States Department of DefenseTerminatedCartilage Damage | Articular Cartilage Disorder of Knee | MicrofracturesUnited States